Richard M. Neve

Frontier Aerospace Corporation (United States) — United States

Immunology and Microbiology · Life Sciences

41h-index14.0kcitations144works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(20), Cancer Mechanisms and Therapy(18), Melanoma and MAPK Pathways(17), PI3K/AKT/mTOR signaling in cancer(16), Ferroptosis and cancer prognosis(16)

Publications144 total

Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation
Structure·2025· 3 cited
Abstract 5949: The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC
Cancer Research·2024· 1 cited
Abstract 5948: FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance
Cancer Research·2024· 6 cited
Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C
Cancer Research·2023· 16 cited
Data from Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
2023Open Access
Supplementary Materials and Methods, Figures S1-5 and Tables S1-8 from Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
2023Open Access
Data from Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
2023Open Access
Supplementary Materials and Methods, Figures S1-5 and Tables S1-8 from Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
2023Open Access
Supplementary Data from Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer
2023Open Access
Data from Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer
2023Open Access
Data from Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer
2023Open Access
Supplementary Data from Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer
2023Open Access
Supplemental Movie 3 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
2023Open Access
Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
2023Open Access
Supplementary Tables 1-3 from An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
2023Open Access
Supplementary Table 4 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
2023Open Access
Supplementary Table 6 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
2023Open Access
Data from Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
2023Open Access
Supplementary Figure 1 from Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
2023Open Access
Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Joe W. Gray(14), Paul T. Spellman(7), Peter M. Haverty(7), Wen-Lin Kuo(6), Christiaan Klijn(6), Richard Bourgon(6), Nancy E. Hynes(6), Nora Bayani(5), Gordon B. Mills(5), David Stokoe(5), Zora Modrušan(5), Heidi S. Feiler(4), Eva Lin(4), Jeff Settleman(4), Zhi Hu(4), Yinghui Guan(4), Bryan T. Hennessy(4), Florian Gnad(4), Frédéric J. de Sauvage(4), Somasekar Seshagiri(4)